Valeant Pharmaceuticals International Inc. and Sprout Pharmaceuticals Inc. have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout for approximately $1 billion plus a share of future profits based upon the achievement of certain milestones. The deal comes on the heels of Sprout’s approval from the U.S. Food and Drug Administration (FDA) for its women’s sexual health drug flibanserin, which will be marketed as Addyi in the U.S. Addyi has de...